Adult Dosing & Uses
Not available in United States
Fluanxol Depot (Flupenthixol Decanoate)
20-40 mg IM preferably in gluteus maximus
Follow with 2nd dose of 20-40 mg 4-10 days after 1st injection, THEN
20-40 mg IM q2-3week
Test first in patients not exposed to long-acting depot antipsychotics, geriatric, frail/cachectic, pts with EPS predisposition with 5 mg IM
May use 10% IM solution on patients requiring higher doses or uncomfortable with large-volume injections
Fluanxol Tabs (Flupenthixol Dihydrochloride)
1 mg TID
May be increased by 1 mg q2-3d
Usual maint dose 3-6 mg/d in divided doses
Up to 12 mg/d has been used
May be switched to IM after stabilization
Other Indications & Uses
Maintenance of chronic schizophrenia without agitation, excitement or hyperactivity
Pediatric Dosing & Uses
Not recommended
Drug Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
EPS (30%)
Frequency Not Defined
Tardive dyskinesia
Pseudoparkinsonism
Dystonia
Akathisia
Dry mouth
Blurred vision
Excessive perspiration
Excessive salivation
Micturition difficulties
Palpitations
Weight change
Elevated prolactin
Galactorrhea
Loss of libido
Impotence
Eosinophilia
Jaundice
Incr liver enzymes (AST, ALT, alk phos)
Nausea
Contraindications & Cautions
Contraindications
Hypersensitivity to thioxanthenes
Severely agitated psychotics, psychoneuroses
CNS depression due to any cause, brain damage, comatose state
Circulatory collapse, blood dyscrasias, pheochromocytoma
Geriatric pts with confusion or agitation
Cardiac or renal insufficiency
Not for IV
Cautions
Pregnancy, lactation, breast cancer, glaucoma, history of convulsive d/o
Potential for tardive dyskinesia on long-term tx
Depot inj: ensure by aspiration after insertion of needle that inadvertent IV inj doesn't occur
Do not use epinephrine if hypotension occurs
Do not use with large doses of hypnotics
Pregnancy & Lactation
Pregnancy Category: not available
Lactation: enters breast milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Peak Plasma Time
IM: 4-7 d
PO: 3-8 hr
Other Information
Metabolism: unknown, apparently inactive metabolites
Excretion: mainly feces, small portion in urine
Mechanism of Action
Thioxanthene, unknown mechanism
